Dr. Reddy's Laboratories Limited (BOM:500124)
1,326.40
+13.65 (1.04%)
At close: Jun 19, 2025
Dr. Reddy's Laboratories Revenue
In the fiscal year ending March 31, 2025, Dr. Reddy's Laboratories had annual revenue of 325.54B INR with 16.61% growth. Dr. Reddy's Laboratories had revenue of 85.06B in the quarter ending March 31, 2025, with 20.09% growth.
Revenue
325.54B
Revenue Growth
+16.61%
P/S Ratio
3.39
Revenue / Employee
11.71M
Employees
27,811
Market Cap
1,102.93B
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Mar 31, 2025 | 325.54B | 46.37B | 16.61% |
Mar 31, 2024 | 279.16B | 33.29B | 13.54% |
Mar 31, 2023 | 245.88B | 31.49B | 14.69% |
Mar 31, 2022 | 214.39B | 24.67B | 13.00% |
Mar 31, 2021 | 189.72B | 15.12B | 8.66% |
Mar 31, 2020 | Pro | Pro | Pro |
Mar 31, 2019 | Pro | Pro | Pro |
Mar 31, 2018 | Pro | Pro | Pro |
Mar 31, 2017 | Pro | Pro | Pro |
Mar 31, 2016 | Pro | Pro | Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
Reliance Industries | 9,646.93B |
HDFC Bank | 2,728.47B |
Tata Consultancy Services | 2,553.24B |
Bharti Airtel | 1,729.85B |
ICICI Bank | 2,006.54B |
State Bank of India | 3,429.39B |
Infosys | 1,647.16B |
Life Insurance Corporation of India | 8,901.58B |
Dr. Reddy's Laboratories News
- 3 days ago - Nifty 50 top losers today, June 17: Adani Enterprises, Dr. Reddy’s, Tata Motors, Sun Pharma lead declines - Business Upturn
- 3 days ago - Pharma stocks in focus as Trump announces tariffs on sector ‘soon’ - Business Upturn
- 4 days ago - Nifty 50 top losers today, June 16: Tata Motors, Dr. Reddy’s, Sun Pharma, Adani Ports and Jio Financial Services - Business Upturn
- 9 days ago - Stocks to watch on June 12: Tata Comm, Max Health, Dr Reddy’s, HDFC Life, PayTM in focus on brokerage views - Business Upturn
- 9 days ago - Nomura upbeat on Dr. Reddy’s long-term prospects; maintains ‘Buy’ call with Rs 1,575 target - Business Upturn
- 14 days ago - Nifty 50 top gainers this week (June 7): Eternal, Shriram Finance, Dr. Reddy’s, Mahindra & Mahindra and more - Business Upturn
- 15 days ago - Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug - Benzinga
- 15 days ago - Dr Reddy's And Alvotech Join Hands To Develop Biosimilar For Merck's Blockbuster Cancer Drug - Benzinga